CGA members will be able to access on-site rapid testing for Covid-19 subject to Health Canada approvals
VANCOUVER, British Columbia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (VS Health or the "Company") a portfolio company of Victory Square Technologies Inc. ("Victory Square'') (CSE:VST) (OTC:VSQTF) (FWB:6F6) has entered into an agreement with the Canadian Gaming Association (CGA), a national trade association representing the leading operators and suppliers in Canadas casino gaming and lottery industry subject to Health Canada approval.
The Company announced on October 6, 2020 that it had submitted all formal documents and research for Health Canada approval of its proprietary Safetest Covid-19 Rapid test. This sales, distribution and testing agreement will enable VS Health to assist the members of one of Canadas largest hospitality industry associations ensuring the health and safety of the 180,000 employees that make up the gaming industry in Canada. Before the industry shut down in March, Canadian casino and bingo operators had over 50 million unique visits annually to their properties.
This Safetest Covid-19 Rapid Testcomplement will allow each participating property to access rapid, easy, efficient and cost-effective daily Covid-19 Rapid tests to ensure employees are not infected with the Covid-19 virus, which will in turn keep workplaces safe. The test may also be administered to customers, subject to Health Canada approvals.
We are very pleased to engage with Victory Square Health, said Paul Burns, President and CEO of the Canadian Gaming Association. We believe that providing access to rapid testing, like the Safetest Rapid Test product, is one of the most important tools to help reopen our economy and to allow for greater confidence in increasing capacities in venues across the hospitality industry.
I am delighted with this important agreement with the CGA so that Victory Square Health may realize its goal of commencing distribution of its exclusive Rapid Test kits on a national scale, said Victory Square CEO Shafin D. Tejani. The gaming and entertainment industries have been adversely affected by this pandemic and we are confident that our products and testing services will enable these properties to reopen and increase capacity through our Covid-19 tests. We look forward to providing our Safetest Rapid Test kits and testing services to all companies affected by Covid-19 following Health Canada approvals so that they can get their teams back to work and help grow our economy.
Victory Square Health is committed to assisting Canadians and Canadian organizations. The company recently announced a strategic partnership with the Canadian Police Association and its members across Canada.
VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansens Disease, Brucellosis, HTLV and blood sample screening tests.
Disclaimer:
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
*These figures have been vetted by the Canadian Gaming Association
Go to: VictorySquare.com and sign up for VSTs official newsletter at http://www.VictorySquare.com/newsletter
On behalf of the board,
Shafin Diamond TejaniChief Executive OfficerVictory Square Technologies
For further information about the Company, please contact:
Investor Relations Contact Alex TziliosEmail: alexandros@victorysquare.comTelephone: 778-867-0482
Media Relations Contact Howard Blank, DirectorEmail: howard@victorysquare.comTelephone: 604-928-6066
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.
VST's sweet spot is the cutting-edge tech that's shaping the 4th Industrial Revolution. Our portfolio consists of 23 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.
What we do differently for startups
VST isn't just another investor. With real skin in the game, we're committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best build, innovate and disrupt. In 24-36 months, you'll scale and be ready to monetize.
What we do differently for investors
VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).
For investors, we offer early-stage access to the next unicorns before they're unicorns.
Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit http://www.victorysquare.com.
ABOUT CGA:
The Canadian Gaming Association (CGA) is a national trade association that works to advance the evolution of Canadas gaming industry. The associations mandate is to promote the economic value of gaming in Canada; use research, innovation, and best practices to help the industry advance; and create productive dialogue among stakeholders.
Forward Looking Statement
This news release contains forward-looking information within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as believes, expects, anticipates, estimates, intends, plans, continues, project, potential, possible, contemplate, seek, goal, or similar expressions, or may employ such future or conditional verbs as may, might, will, could, should or would, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022
- BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India - June 8th, 2022
- Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance - June 8th, 2022
- Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal - June 8th, 2022
- 57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News - June 8th, 2022
- Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com - June 8th, 2022
- Inspiration for the laboratory of tomorrow - Chemie.de - June 8th, 2022
- Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia... - May 8th, 2022
- The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance - May 8th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 8th, 2022
- Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic - May 8th, 2022
- Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News - May 8th, 2022
- Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes - May 8th, 2022
- Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English - May 8th, 2022
- Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express - May 8th, 2022
- CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News - January 30th, 2022
- SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire - January 30th, 2022
- Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center - January 30th, 2022
- (New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug... - January 30th, 2022
- Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health - January 30th, 2022
- Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA - January 30th, 2022